This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
FDA Issues Warning About Proton Pump Inhibitors
Studies Show Link Between PPI Use, Increased Fracture Risk, Other Adverse Effects
By News Staff
Prescription PPIs reduce the amount of acid in the stomach and are used to treat such conditions as gastroesophageal reflux disease, stomach and small intestine ulcers, and esophagitis. The affected products are
- esomeprazole, which is marketed as Nexium and, in combination with naproxen, as Vimovo;
- dexlansoprazole, which is marketed as Dexilant;
- omeprazole, which is marketed as Prilosec and, in combination with sodium bicarbonate, as Zegerid;
- lansoprazole, which is marketed as Prevacid;
- pantoprazole, which is marketed as Protonix; and
- rabeprazole, which is marketed as Aciphex.
- omeprazole, which is marketed as Prilosec OTC and, in combination with sodium bicarbonate, as Zegerid OTC; and
- lansoprazole, which is marketed as Prevacid 24HR.
In addition, FDA officials advised physicians to follow the dosage recommendations contained in the prescription product labeling and consider whether a lower dosage or shorter duration of PPI therapy would adequately treat a patient's condition.
Patients at risk for osteoporosis should have their bone density status managed according to current clinical practice, and, if indicated, should take vitamin D and calcium supplements, the agency said.
The FDA said its actions were based on a review of seven studies, six of which reported an increased risk of fractures of the hip, wrist and/or spine. The agency's review included one study published May 10 in the Archives of Internal Medicine that found that postmenopausal women who used PPIs had a 26 percent increased risk for forearm and wrist fractures, a 47 percent increased risk for spine fractures, and a 25 percent increased risk for total fractures.
Another study in the same journal issue found that increasing levels of pharmacologic acid suppression are associated with increased risks for nosocomial Clostridium difficile infection; the risk was greatest among patients who used PPIs more than once per day. The drugs also are associated with recurrent C.difficile infection, according to another study in the same journal.
Yet another study in that Archives issue found that high-dose PPIs, when compared with low-dose PPIs, do not further reduce the rates of rebleeding, need for surgical intervention or mortality after endoscopic treatment in patients with bleeding peptic ulcers.
Finally, the same journal issue also contained an editorial that noted that PPIs are the third-highest selling class of drugs in the United States, with $13.9 billion in annual sales. The drugs are overprescribed, the author said, with more than two-thirds of PPI prescriptions written for inappropriate indications. He urged physicians to "offer treatments other than PPIs for functional dyspepsia, prescribe short courses of PPI treatment (after disclosure of possible risks and benefits), and consider a trial of discontinuing PPI therapy in patients who are asymptomatic."
FDA Advises Against Use of Clopidogrel With Omeprazole, Other Drugs
Drug Interaction Reduces Effect of Anticlotting Medication
News Briefs: Week of March 8-12: FDA Approves Name Change for Heartburn Drug
FDA Drug Safety Communication: "Possible Increased Risk of Fractures of the Hip, Wrist and Spine With the Use of Proton Pump Inhibitors"
(May 25, 2010)
Archives of Internal Medicine: "Less Is More: Proton Pump Inhibitor Use, Hip Fracture and Change in Bone Mineral Density in Postmenopausal Women"
(May 10, 2010)